Nader Shaikh1, Howard E Rockette, Alejandro Hoberman, Marcia Kurs-Lasky, Jack L Paradise. 1. From the *Division of General Academic Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine; and †Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA.
Abstract
BACKGROUND: We previously developed and validated the acute otitis media severity of symptom (AOM-SOS) scale for rating symptoms of AOM in young children. In this report, we sought to estimate the minimal important difference (MID) for change in AOM-SOS scores. METHODS: In a group of children 6-24 months of age with AOM enrolled in a recently reportedplacebo-controlled clinical trial of antibiotic efficacy, we compared changes in AOM-SOS scores with parental assessments of change over a 24-hour period. Mean absolute and mean relative change in scores in children reportedly exhibiting only a small degree of improvement were considered in arriving at an estimated MID. We then compared the proportions of children in the antibiotic and placebo groups, respectively, whose AOM-SOS scores changed more than the estimated MID at various time points after enrollment. RESULTS: Data were available for 277 children. Children whose parents reported only a small degree of improvement 24 hours after enrollment had a mean decrease in AOM-SOS score of 3.8, or 55%, from baseline. We found the relative decrease more telling than the absolute decrease. The proportions of children in the antibiotic and placebo groups, respectively, whose AOM-SOS scores had decreased <55% on Day 7 were 12.3 and 23.8% (P=0.02), and during Days 4-7 were 28 and 40% (P=0.046). CONCLUSIONS: We estimated the MID for change in AOM-SOS scores in young children and described use of the MID as an added metric in interpreting results from a clinical trial of antibiotic efficacy.
RCT Entities:
BACKGROUND: We previously developed and validated the acute otitis media severity of symptom (AOM-SOS) scale for rating symptoms of AOM in young children. In this report, we sought to estimate the minimal important difference (MID) for change in AOM-SOS scores. METHODS: In a group of children 6-24 months of age with AOM enrolled in a recently reported placebo-controlled clinical trial of antibiotic efficacy, we compared changes in AOM-SOS scores with parental assessments of change over a 24-hour period. Mean absolute and mean relative change in scores in children reportedly exhibiting only a small degree of improvement were considered in arriving at an estimated MID. We then compared the proportions of children in the antibiotic and placebo groups, respectively, whose AOM-SOS scores changed more than the estimated MID at various time points after enrollment. RESULTS: Data were available for 277 children. Children whose parents reported only a small degree of improvement 24 hours after enrollment had a mean decrease in AOM-SOS score of 3.8, or 55%, from baseline. We found the relative decrease more telling than the absolute decrease. The proportions of children in the antibiotic and placebo groups, respectively, whose AOM-SOS scores had decreased <55% on Day 7 were 12.3 and 23.8% (P=0.02), and during Days 4-7 were 28 and 40% (P=0.046). CONCLUSIONS: We estimated the MID for change in AOM-SOS scores in young children and described use of the MID as an added metric in interpreting results from a clinical trial of antibiotic efficacy.
Authors: Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Nader Shaikh; Ellen R Wald; Diana H Kearney; D Kathleen Colborn; Marcia Kurs-Lasky; Sonika Bhatnagar; Mary Ann Haralam; Lisa M Zoffel; Carly Jenkins; Marcia A Pope; Tracy L Balentine; Karen A Barbadora Journal: N Engl J Med Date: 2011-01-13 Impact factor: 91.245
Authors: Nader Shaikh; Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Marcia Kurs-Lasky; D Kathleen Colborn; Diana H Kearney; Lisa M Zoffel Journal: Pediatr Infect Dis J Date: 2009-01 Impact factor: 2.129
Authors: Nader Shaikh; Alejandro Hoberman; Jack L Paradise; Ellen R Wald; Galen E Switze; Marcia Kurs-Lasky; D Kathleen Colborn; Diana H Kearney; Lisa M Zoffel Journal: Pediatr Infect Dis J Date: 2009-01 Impact factor: 2.129
Authors: Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Diana H Kearney; Sonika Bhatnagar; Timothy R Shope; Judith M Martin; Marcia Kurs-Lasky; Susan J Copelli; D Kathleen Colborn; Stan L Block; John J Labella; Thomas G Lynch; Norman L Cohen; MaryAnn Haralam; Marcia A Pope; Jennifer P Nagg; Michael D Green; Nader Shaikh Journal: N Engl J Med Date: 2016-12-22 Impact factor: 91.245
Authors: Nader Shaikh; Ellen R Wald; Jong-Hyeon Jeong; Marcia Kurs-Lasky; David Nash; Michael E Pichichero; Diana H Kearney; Mary Ann Haralam; A'Delbert Bowen; Lynda L Flom; Alejandro Hoberman Journal: J Pediatr Date: 2018-12-10 Impact factor: 4.406
Authors: Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Jong-Hyeon Jeong; Diana H Kearney; Sonika Bhatnagar; Timothy R Shope; Gysella Muñiz; Judith M Martin; Marcia Kurs-Lasky; MaryAnn Haralam; Marcia A Pope; Jennifer P Nagg; Wenchen Zhao; Mohammad Kowser Miah; Jan Beumer; Raman Venkataramanan; Nader Shaikh Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Alejandro Hoberman; Diego Preciado; Jack L Paradise; David H Chi; MaryAnn Haralam; Stan L Block; Diana H Kearney; Sonika Bhatnagar; Gysella B Muñiz Pujalt; Timothy R Shope; Judith M Martin; Daniel E Felten; Marcia Kurs-Lasky; Hui Liu; Kristin Yahner; Jong-Hyeon Jeong; Norman L Cohen; Brian Czervionke; Jennifer P Nagg; Joseph E Dohar; Nader Shaikh Journal: N Engl J Med Date: 2021-05-13 Impact factor: 91.245